Eledon Pharmaceuticals, Inc. (ELDN)
Automate Your Wheel Strategy on ELDN
With Tiblio's Option Bot, you can configure your own wheel strategy including ELDN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ELDN
- Rev/Share 0.005
- Book/Share 1.3742
- PB 1.55
- Debt/Equity 0.0076
- CurrentRatio 8.1204
- ROIC -0.6857
- MktCap 127548181.0
- FreeCF/Share -0.8363
- PFCF -1.9766
- PE 11.2233
- Debt/Assets 0.0055
- DivYield 0
- ROE 0.1412
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 3
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | ELDN | H.C. Wainwright | -- | Buy | -- | $9 | June 18, 2025 |
| Initiation | ELDN | Guggenheim | -- | Buy | -- | $9 | Jan. 28, 2025 |
News
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Phase II BESTOW Trial Results and Advances in Transplantation Immunosuppression Transcript
Published: November 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Eledon Pharmaceuticals, Inc. ( ELDN ) Discusses Phase II BESTOW Trial Results and Advances in Transplantation Immunosuppression November 7, 2025 8:00 AM EST Company Participants David-Alexandre Gros - CEO & Non Independent Director Eliezer Katz - Chief Medical Officer Steven Perrin - President, Chief Scientific Officer & Non Independent Director Paul Little - Chief Financial Officer Conference Call Participants Thomas Smith - Leerink Partners LLC, Research Division Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Rami Katkhuda - LifeSci Capital, LLC, Research Division Vamil Divan - Guggenheim Securities, LLC, Research Division Robert LeBoyer - NOBLE Capital Markets, Inc., Research …
Read More
Eledon Pharmaceuticals' Lead Asset Fails In Mid-Stage Study, But Pushes Forward With Pivotal Study
Published: November 07, 2025 by: Benzinga
Sentiment: Negative
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) stock is trading lower on Friday, with a session volume of 15.72 million, compared to its average volume of 1.24 million, according to Benzinga Pro. The company announced results from its Phase 2 BESTOW trial of tegoprubart for the prevention of organ rejection in patients receiving a de novo kidney transplant.
Read More
Best Momentum Stocks to Buy for July 14th
Published: July 14, 2025 by: Zacks Investment Research
Sentiment: Positive
ELDN, KDDIY and PENG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 14, 2025.
Read More
New Strong Buy Stocks for July 14th
Published: July 14, 2025 by: Zacks Investment Research
Sentiment: Positive
WIT, KNOP, PENG, ELDN and KDDIY have been added to the Zacks Rank #1 (Strong Buy) List on July 14, 2025.
Read More
What Makes Eledon Pharmaceuticals (ELDN) a New Buy Stock
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Eledon Pharmaceuticals (ELDN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
About Eledon Pharmaceuticals, Inc. (ELDN)
- IPO Date 2014-09-17
- Website https://eledon.com
- Industry Biotechnology
- CEO David-Alexandre C. Gros
- Employees 31